?-Synuclein phosphorylated at Serine 129 is a marker of pathologic fibrillar aggregates in hallmark Lewy body inclusions in Parkinson's disease (PD) and Dementia with Lewy Bodies, but the precise reason for this post- translational modification and its role in the pathogenesis of these disorders remain unclear. This project aims to address this knowledge gap by studying the role that protein phosphatase 2A (PP2A) mediated dephosphorylation of ?-synuclein plays in the molecular etiology of these disorders. PP2A is a member of a family of conserved enzymes that constitute the majority of serine/threonine phosphatase activity in the brain and function as master regulators of cellular phosphoregulatory networks, controlling key processes required for protein homeostasis and cell survival. PP2A is a trimeric enzyme composed of a catalytic C subunit, a scaffolding A subunit, and a regulatory B subunit each of which is encoded by multiple genes and multiple splice isoforms. The substrate specificity of PP2A is determined by its subunit composition, which is regulated by methylation of its catalytic C subunit, and this methylation is controlled by both a dedicated methylesterase, PME-1, and a dedicated methyltransferase, LCMT-1. The PP2A isoform responsible for dephosphorylating ?-synuclein is methylation dependent, and pharmacological inhibition of PME-1-dependent PP2A demethylation mitigates the phenotype of ?-synuclein transgenic mice. To study the role of PP2A and its methylation in ?-synucleinopathies, we will alter PP2A activity in vivo by manipulating PME-1 and LCMT-1 expression using genetically modified mice.
Specific aim 1 will test the hypothesis that reducing PP2A methylation, via increased PME-1 expression, exacerbates ?-synucleinopathies by increasing the pathogenicity of ?-synuclein.
Aim 2 will test the hypothesis that enhancing PP2A methylation, via increased LCMT-1 expression, protects against ?-synucleinopathies by reducing the pathogenicity of ?-synuclein.
And aim 3 will determine if manipulating PP2A methylation impacts ?-synuclein mediated pathology through phosphorylation at Serine 129. By the completion of these studies we will gain greater insight into the pathogenetic role of PP2A in ?-synucleinopathies and advance it as a potential disease modifying therapeutic target for these disorders.

Public Health Relevance

The aim of this project is to elucidate how the enzyme, Protein Phosphatase 2A, contributes to the abnormal aggregation and toxicity of ?-synuclein, a key protein in the brains of individuals with Parkinson's disease and Dementia with Lewy Bodies. Insight gained about this process can lead to new approaches to developing disease modifying therapies for these disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS101134-04
Application #
9920223
Study Section
Clinical Neuroplasticity and Neurotransmitters Study Section (CNNT)
Program Officer
Sieber, Beth-Anne
Project Start
2017-05-01
Project End
2022-04-30
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
4
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Rbhs-Robert Wood Johnson Medical School
Department
Neurology
Type
Schools of Medicine
DUNS #
078795875
City
Piscataway
State
NJ
Country
United States
Zip Code
08854
Oh, Stephanie E; Park, Hye-Jin; He, Liqiang et al. (2018) The Parkinson's disease gene product DJ-1 modulates miR-221 to promote neuronal survival against oxidative stress. Redox Biol 19:62-73
Oh, Stephanie E; Mouradian, M Maral (2018) Cytoprotective mechanisms of DJ-1 against oxidative stress through modulating ERK1/2 and ASK1 signal transduction. Redox Biol 14:211-217
Park, Hye-Jin; Lee, Kang-Woo; Oh, Stephanie et al. (2018) Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease. J Neuropathol Exp Neurol 77:139-148
Yan, Run; Zhang, Jie; Park, Hye-Jin et al. (2018) Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson's disease and DLB. Proc Natl Acad Sci U S A 115:E12053-E12062
Oh, Stephanie E; Mouradian, M Maral (2017) Regulation of Signal Transduction by DJ-1. Adv Exp Med Biol 1037:97-131
Asam, Kesava; Staniszewski, Agnieszka; Zhang, Hong et al. (2017) Eicosanoyl-5-hydroxytryptamide (EHT) prevents Alzheimer's disease-related cognitive and electrophysiological impairments in mice exposed to elevated concentrations of oligomeric beta-amyloid. PLoS One 12:e0189413
Park, Hye-Jin; Lee, Kang-Woo; Park, Eun S et al. (2016) Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies. Ann Clin Transl Neurol 3:769-780